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Abstract Background: Small-bowel tumors are rare and account for 1e2% of all
gastrointestinal neoplasms. Most of these tumors are found at surgery indicated
for other diagnosis or intestinal obstruction. The rarity, unclear presentation and
diagnostic difficulty of these tumors stimulated our interest to review our experi-
ence with emergency surgery for intestinal obstruction secondary to jejunoileal
tumors.
Methods: We reviewed 17 patients operated on for intestinal obstruction secondary
to benign and malignant primary tumors of jejunum and ileum at our institution the
last 10 years.
Results: The series comprised 8 male and 9 female patients, most of them younger
than 49 years of age. The most frequent tumors found were GIST (36%) followed by
lymphomas (24%) and adenocarcinomas (18%). Most tumors (65%) were located in
the ileum. Mean survival for patients with malignant tumors was 19.5  13 months,
and for patients with benign tumors 72  20 months (p < 0.05).
Conclusion: Jejunoileal tumors present frequently in patients younger than
49 years of age. Ileal tumors are more likely to develop intestinal obstruction than
jejunal tumors. Emergency surgery for these patients precludes a complete and
negative margin resection and constitutes a risk factor for residual disease and
short-term survival.
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Small-bowel tumors are extremely rare and account
for only 1e2% of all gastrointestinal (GI) neo-
plasms.1,2 Symptoms and signs of small-bowel
tumors are vague, unspecific and frequently areublished by Elsevier Ltd. All rights reserved.
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sequence these tumors often go untreated for pro-
longed periods because they are notoriously
difficult to diagnose.1,3 Most of these tumors are
found at surgery indicated for other diagnosis3,4
or intestinal obstruction.5,6 In fact, it has been
reported that around 50% of patients with benign
and primary malignant jejunoileal tumors presents
with intestinal obstruction.3,6 The most frequent
clinical presentations of jejunoileal tumors are re-
current abdominal pain, palpable abdominal mass,
intestinal obstruction or perforation, and GI hemor-
rhage.1e6 Because most patients with small-bowel
primary malignant tumors have a poor prognosis
due to advanced-stage presentations,2,6,7 the pri-
mary goals of treatment are conservative and
mainly palliative, including alleviation of pain, nau-
sea and vomiting.5,6 The rarity, unclear presenta-
tion and diagnostic difficulty of jejunoileal tumors
stimulated our interest to review our experience
with their treatment during emergency surgery for
intestinal obstruction.
Patients and methods
From January 1995 to December 2005, 277 patients
were operated on for intestinal obstruction at our
institution (Table 1). A retrospective review of the
clinical records of these patients identified 17 cases
(6%) with benign and malignant primary tumors of
jejunum and ileum, of them 14 tumors (82%) were
classified as malignant and 3 (18%) as benign.
Mean age was 49  17 years (25e73 years); 9
patients (53%) were male and 8 (47%) female.
Mean length of stay was 21  15 days (9e65 days).
Table 1 Etiology of intestinal obstruction in 277
patients
N (%)
Hernias 126 (45)
Adhesions 41 (15)
Colonic primary tumors 23 (8)
Metastasis 16 (6)
Jejunoileal malignant tumors 14 (5)
Colonic volvulus 14 (5)
Meckel’s diverticulum 10 (4)
Fecaloma 8 (3)
Complicated appendicitis 7 (2.5)
Gallstone ileus 7 (2.5)
Jejunoileal benign tumors 3 (1)
Duodenal primary tumors 3 (1)
Ileal endometriosis 2 (0.7)
Cro¨hn’s disease 2 (0.7)
Diaphragmatic disease of the ileum 1 (0.4)Patients with metastatic tumors, colonic and duo-
denal primary tumors were excluded. Parameters
obtained from the clinical records were patients’
demographic data, clinical presentation, associ-
atedmorbidity, tumor location, surgical procedure,
pathologic findings, postoperative complications,
follow-up and survival.
Surgical procedure, histology and
classification
Operative management consisted of en bloc tumor
resection including adjacent infiltrated structures
with curative intent in all cases; however only in 7
patients (41%) was the histological surgical margin
negative. Tumors were categorized into the follow-
ing histological types: adenocarcinoma, sarcoma,
leiomyoma (before year 2001), gastrointestinal
stromal tumors (GIST) (after year 2001) and lym-
phoma. Pathologic parameters analyzed for adeno-
carcinomas were histologic differentiation, depth
of invasion, regional lymph node status, margin
status and stage according to the American Joint
Committee on Cancer (AJCC).8 Pathologic parame-
ters analyzed for sarcomas were histologic grade,
tumor size, regional lymph node status and stage
according to the American Joint Committee on Can-
cer (AJCC).8 Pathologic parameters analyzed for
GISTs were patient age, Ki-67 proliferative index
greater than 0.82, recurrence and curative or palli-
ative surgery.9 Immunohistochemical markers stud-
ied were CD117, CD34, S100, a-smoothmuscle actin
(a-SMA) and desmin. Pathologic parameters ana-
lyzed for lymphomas were involvement of single
or multiple nodal groups on one or both sides of
the diaphragm and compromise of bone marrow,
central nervous system or diffuse visceral involve-
ment according to the Ann Arbor Staging System.10
Statistics
Data was presented as proportions, mean, stan-
dard deviation and range, and analyzed with Chi-
square test. A multivariate regression logistic
model was employed to identify specific signs
and symptoms of jejunoileal tumors and differen-
tiate their clinical presentation of intestinal ob-
struction from other causes. The analysis was
performed with the statistical software SPSS
version 11.0 (Chicago, Illinois, USA).
Results
The most common tumors found were GISTs (36%)
followed by lymphomas (24%) and adenocarcinomas
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Location Histologic type
Adenocarcinoma
(N ¼ 3)
Sarcoma
(N ¼ 2)
Leiomyoma
(N ¼ 2)
GIST
(N ¼ 6)
Lymphoma
(N ¼ 4)
Jejunum (6e35%) e 1 2 2 1
Ileum (11e65%) 3 1 e 4 3
Total (17e100%) (%) 3 (18) 2 (12) 2 (12) 6 (36) 4 (24)
Ileal vs jejunal tumors: p < 0.05.(18%). Most tumors (65%) were located in the ileum
(Table 2). Seven patients (41%) did not have associ-
ated morbidity; the most common associated mor-
bidity was chronic anemia in 7 patients (Table 3).
All patients presented with an acute abdomen.
Most patients (65%) were younger than 49 years of
age (p < 0.05). Nine patients had associated weight
loss, 12 patients had acute anemia and in 5 patients
an abdominalmasswas palpated (Table 4). Themul-
tivariate regression logistic model identified the
presenceof anabdominal hernia as theonly physical
sign specific to rule-out thepresenceof a jejunoileal
tumor and failed to identify any specific symptom to
differentiate the presence of small-bowel tumors
from other causes of intestinal obstruction.
Table 5 describes the preoperative studies; in
13 patients (76%) abdominal plain films were per-
formed, barium enema in 4 patients, upper gas-
trointestinal series and enteroclysis in one
patient each; in 2 patients no radiographs were
taken. Ultrasound was performed in 9 patients,abdominal computed tomographic scan (CT scan)
in 1 patient and upper endoscopy in 4. Table 6
describes the surgical findings; most tumors
were described as obstructive (94%). Thirteen tu-
mors were solitary, 4 were smaller than 5 cm and
7 larger than 11 cm. Table 7 shows the patholog-
ical findings and tumor stage for adenocarcinoma
and sarcoma. Two patients were T4, four patients
had lymphatic involvement, two patients had a
positive margin and two had poorly differentiated
tumors. One patient was in Stage I, two patients
in Stage II and two patients in Stage III. Regarding
tumor size, only one patient had a tumor larger
than 11 cm. Table 8 shows the pathological find-
ings and tumor stage for GIST and lymphoma.
Most patients (78%) were younger than 49 years
of age. In patients with GISTs, all had a Ki prolifera-
tive index >0.82. Surgery was macroscopically
considered curative in 4 patients and palliative in
5. In 8 patients the surgical margin was positive.
Regarding immunochemistry for GISTs, all of themTable 3 Co-morbiditya
Histologic type
Adenocarcinoma
(N ¼ 3)
Sarcoma
(N ¼ 2)
Leiomyoma
(N ¼ 2)
GIST
(N ¼ 6)
Lymphoma
(N ¼ 4)
Total
N (%)
Chronic anemia 1 1 e 4 1 7 (41)
Digestive hemorrhage 1 e e 1 1 3 (18)
Chronic diarrhea 1 1 e e e 2 (12)
Chronic lung diseases e 1 e e e 1 (6)
High blood pressure 1 e e e e 1 (6)
Previously operated
colonic cancer
e e 1 e e 1 (6)
Previous gynecological
surgery
e e 1 e e 1 (6)
Duodenal ulcer e e e 1 e 1 (6)
Chronic urinary tract
infection
e e e 1 e 1 (6)
Diabetes e e e e 1 1 (6)
Neurofibromatosis e e e 1 e 1 (6)
None 1 1 e 2 3 7 (41)
a Any patient could have one or more associated morbidities.
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Histologic type
Adenocarcinoma
(N ¼ 3)
Sarcoma
(N ¼ 2)
Leiomyoma
(N ¼ 2)
GIST
(N ¼ 6)
Lymphoma
(N ¼ 4)
Total
N (%)
Age <49 years old e 1 2 5 3 11 (65)
Age >49 years old 3 1 e 1 1 6 (35)
Acute abdomen 3 2 2 6 4 17 (100)
Abdominal pain 3 2 2 6 4 17 (100)
Acute anemia 3 2 e 3 4 12 (70)
Nausea/vomiting 2 1 1 4 3 11 (65)
Abdominal distention 3 2 e 2 2 9 (53)
Weight loss 3 2 e e 4 9 (53)
Abdominal mass 1 1 e 1 2 5 (29)
Diarrhea e e e 1 3 4 (24)
Digestive hemorrhage 1 1 e 1 e 3 (18)
Urinary tract infection e e e 1 e 1 (6)
a Any patient could have one or more symptoms or signs at presentation. Patients <49 years of age vs patients >49 years old:
p < 0.05.were CD117 positive, 3 patients were also CD34
positive. According to the Ann Arbor Staging System
for lymphoma 2 patients were in Stage II.
In 7 patients there were no immediate post-
operative complications, 5 patients had surgical
site infection, 2 had intestinal fistula and 1 patient
suffered mesenteric ischemia. The patient who had
mesenteric ischemia developed intestinal necrosisand sepsis and died after 65 days after his initial
surgery (Table 9). Table 10 describes the follow-up
and survival. Mean survival for patients with malig-
nant tumors was 19.5  13 months (2e38 months),
and for patients with benign tumors 72  20 months
(51e90 months) (p < 0.05). Five (36%) of 14 patients
with malignant tumors and all patients with benign
tumors have survived to date.Table 5 Radiologic and endoscopic studies
Case Gender Age Abdominal x-rays Ultrasound Endoscopy CT scan Location Histology
1 F 57 Plain films No No No Ileum Sarcoma
2 F 54 Plain films No No No Jejunum Leiomyoma
3 F 68 Plain films þ barium
enema
No No No Ileum Adenocarcinoma
4 M 29 Plain films þ barium
enema
No No No Ileum Non-Hodgkin’s
lymphoma
5 M 67 Plain films No No No Ileum Adenocarcinoma
6 F 46 Plain films Yes No No Jejunum Leiomyoma
7 F 63 Barium enema Yes No No Ileum Non-Hodgkin’s
lymphoma
8 M 45 Plain films þ upper
gastrointestinal series
Yes Yes No Jejunum Sarcoma
9 M 73 Barium enema Yes Yes No Ileum Adenocarcinoma
10 M 28 No No No No Jejunum Non-Hodgkin’s
lymphoma
11 F 25 Plain films Yes No No Ileum GIST
12 F 39 Plain films No No No Ileum GIST
13 F 32 Plain films þ
enteroclysis
Yes Yes No Jejunum GIST
14 M 71 Plain films Yes No No Ileum Non-Hodgkin’s
lymphoma
15 M 35 Plain films Yes No No Ileum GIST
16 F 33 No Yes No No Ileum GIST
17 F 37 Plain films No Yes Yes Jejunum GIST
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Macroscopic appearancea Histologic type
Adenocarcinoma
(N ¼ 3)
Sarcoma
(N ¼ 2)
Leiomyoma
(N ¼ 2)
GIST
(N ¼ 6)
Lymphoma
(N ¼ 4)
Total
N (%)
Obstructive 3 2 1 6 4 16 (94)
Necrotic and ulcerated 3 1 e 1 4 9 (53)
Mesenteric and lymphatic
involvement
2 2 e 2 2 8 (47)
Perforated e 2 e e 1 3 (18)
Volvulated e e 1 e e 1 (6)
Number of tumors
Solitary 3 1 2 5 2 13 (76)
Multiple (>2) e 1 e 1 2 4 (24)
Tumor size
<5 cm 1 1 1 1 e 4 (24)
6e10 cm 2 e 1 1 2 6 (35)
>11 cm e 1 e 4 2 7 (41)
a Any tumor could have one or more macroscopic features.Discussion
The small intestine accounts for approximately 75%
of the length and 90% of the mucosal surface of the
gastrointestinal tract; despite this large surface
small-bowel tumors are rare and account for less
than 2% of all GI tumors.1,2,6,7,11e13 Primary benign
or malignant tumors of the jejunum and ileum are
even more rare,3,7 because most small-bowel tu-
mors are found in the duodenum.1,2,7,11 Intestinal
obstruction accounts from 12% to over 50% clinical
presentations of jejunoileal tumors,1,3,6,7,11 Atour institution jejunoileal tumors presenting with
an acute abdomen and operated for intestinal ob-
struction account for 85% of all jejunoileal tumors
operated the last 10 years. Benign and malignant
tumors of the small bowel can occur at any age12
with a mean age at presentation of 50 years,3,6
and have a male to female difference of 2:1. In
this series, the male to female ratio was 1:1 and
the mean age 49 years.
Small-bowel tumors often go untreated for pro-
longed periods because they are a challenging
problem for diagnosis and treatment.1,3,7,11 ClinicalTable 7 Pathologic findings and tumor stage for adenocarcinoma and sarcoma
Histologic type
Adenocarcinoma
(N ¼ 3)
Sarcoma
(N ¼ 2)
Total
N (%)
T1 1 1 2 (40)
T2 e e e
T3 1 e 1 (20)
T4 1 1 2 (40)
N0 1 e 1 (20)
N1 2 2 4 (80)
Positive margin 1 1 2 (40)
Grade of differentiation
Well differentiated/low grade 1 e 1 (20)
Moderate/intermediate grade differentiation 1 1 2 (40)
Poor/high grade differentiation 1 1 2 (40)
Stage I 1 e 1 (20)
Stage II 1 1 2 (40)
Stage III 1 1 2 (40)
Stage IV e e e
Tumor size
<5 cm 1 1 2 (40)
6e10 cm 2 e 2 (40)
>11 cm e 1 1 (20)
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fic,1e3 or associated with other diseases.4 Some ret-
rospective studies have tried to clarify the natural
history and clinical presentation of small-bowel
tumors however the lack of specific signs and symp-
toms has precluded this objective.2,6,11 Jejunoileal
tumors are suspected only under extreme condi-
tions such as the presence of a palpable abdominal
Table 8 Pathologic findings and tumor stage for
GIST and lymphoma
Histologic type
GIST
(N ¼ 5)
Lymphoma
(N ¼ 4)
Total
N (%)
Patient age
<49 years old 4 3 7 (78)
>49 years old 1 1 2 (22)
Ki proliferative
index >0.82
5 e e
Surgery
Curative 3 1 4 (44)
Palliative 2 3 5 (55)
Positive margin 4 4 8 (89)
Immunohistochemistry
CD117 5 e e
CD34 3 e e
S100 1 e e
a-smooth muscle
actin (a-SMA)
2 e e
Desmin 1 e e
Ann Arbor Staging System
I e 1 e
II e 2 e
III e e e
IV e 1 e
Tumor size
6e10 cm 1 2 3 (33)
>11 cm 4 2 6 (67)
Table 9 Postoperative complicationsa
Complications N (%)
<30 daysa
None 7 (41)
Surgical site infection 5 (29)
Prolonged postoperative ileus 4 (24)
Intestinal fistula 2 (12)
Mesenteric ischemia 1 (6)
Pneumonia 1 (6)
>30 days
None 15 (88)
Intestinal necrosis and sepsis 1 (6)
Suture fistulous tract 1 (6)
a Any patient could have one or more complications.mass, gastrointestinal hemorrhage, intestinal per-
foration or obstruction6; other reported symptoms
were abdominal pain, weight loss, nausea and vom-
iting, chronic anemia, diarrhea, and jaundice.1e
5,7,11e16 Our patients had similar symptoms. These
symptoms occur with most GI malignancies and
many benign GI conditions.7 It has been suggested
that the clinical presentation of intestinal obstruc-
tion with associated anemia and gastrointestinal
hemorrhage in patients older than 40 years should
raise the suspicion of a malignant jejunoileal
tumor.6 These were the characteristics presented
frequently in our patients; 7 patients had chronic
anemia, 3 digestive hemorrhage and 2 chronic
diarrhea. Predisposing risk factors for small-bowel
malignant tumors are Cro¨hn’s disease, familial
adenomatous polyposis, hereditary non-polyposis
cancer, other GI polyposis, and celiac disease7,17,18;
none of these risk factors were present in our
patients.
The patients of this series were operated for the
diagnosis of intestinal obstruction; consequently
the finding of a small-bowel tumor was unexpected.
They were preoperatively studied principally with
plain abdominal x-rays. Plain abdominal films are
diagnostic only in 50e60% of cases for intestinal
obstruction; enteroclysis with water-soluble con-
trast is more sensible for the diagnosis of intestinal
obstruction.19 Abdominal CT scan and ultrasonogra-
phy have been used for the diagnosis of intestinal
obstruction and have been found to be very use-
ful,19,20 we used ultrasonography and abdominal
CT scan in a few cases with only limited utility. Un-
like our experience, most series performed abdom-
inal CT scan, extended upper endoscopy and
enteroclysis,3,7,12,19 however they reported on
elective and emergency surgery patients.
Endoscopic studies are useful only for duodenal
tumors,1,12 and colonoscopy for colonic tumors.3
Before the introduction of wireless capsule endos-
copy (WCE), enteroclysis was the most effective
diagnostic study for jejunoileal tumors.3,16 We per-
formed only 1 enteroclysis in our patients, the re-
sult being negative for a jejunoileal tumor; this
patient had a jejunal obstructive GIST. For jejunoi-
leal tumors the gold standard for diagnosis was un-
til recently the small-bowel follow-through or
enteroclysis,3,7,12,16 however the introduction and
establishment of WCE will likely change that gold
standard, at least in the elective setting. WCE
has increased the preoperative diagnosis of these
tumors16,21e24; as a consequence, they are cur-
rently diagnosed early and electively operated
with increased frequency. Nonetheless WCE is
not widely available, and furthermore, is contrain-
dicated in suspected intestinal obstruction,
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Case Gender Age Location Histology Follow-up
(years)
Survival
(months)
Alive
1 F 57 Ileum Sarcoma 3 37 No
2 F 54 Jejunum Leiomyoma 7 90 Yes
3 F 68 Ileum Adenocarcinoma 2 25 No
4 M 29 Ileum Non-Hodgkin’s lymphoma <1 3 No
5 M 67 Ileum Adenocarcinoma <1 8 No
6 F 46 Jejunum Leiomyoma 6 75 Yes
7 F 63 Ileum Non-Hodgkin’s lymphoma 2 23 No
8 M 45 Jejunum Sarcoma 1 6 No
9 M 73 Ileum Adenocarcinoma <1 5 No
10 M 28 Jejunum Non-Hodgkin’s lymphoma <1 2 No
11 F 25 Ileum GIST 4 51 Yes
12 F 39 Ileum GIST 3 36 Yes
13 F 32 Jejunum GIST 3 38 Yes
14 M 71 Ileum Non-Hodgkin’s lymphoma 2 27 No
15 M 35 Ileum GIST 2 25 Yes
16 F 33 Ileum GIST 2 24 Yes
17 F 37 Jejunum GIST 1 14 Yestherefore most jejunoileal tumors will continue
being studied, at least in the emergency setting,
with enteroclysis and frequently operated on an
emergency basis and not under elective
conditions.
The aims of surgery for intestinal obstruction
secondary to small-bowel tumor are the alleviation
of symptoms related to the obstruction, improve-
ment of the quality of life and extension of the
survival time.5 At emergency surgery these goals
are difficult to meet. For intestinal obstruction
secondary to jejunoileal tumors, resection of the
obstructed segment may afford the best out-
come.5,11 If resection cannot be done safely, or
a prohibitive amount of dissection is needed, alter-
native approaches should be considered such as
a bypass procedure.5 Segmental bowel resection
generally provides sufficient margins for adenocar-
cinomas7,11 and other jejunoileal tumors.
Reports on small-bowel tumors frequently in-
clude duodenal tumors; consequently the most
common tumor reported was adenocarcinoma.1,11
Other reports have included metastasis to the small
bowel from tumors located in the lung and breast.1
For jejunoileal tumors, the most common location
has been reported to be the jejunum in 67% of
cases, however this report was from a Chinese se-
ries3 claiming to be different from western studies;
in our own experience, these tumors are more fre-
quently found in the ileum being the cause of intes-
tinal obstruction in 65% of all patients. The
reported incidence of patients with intestinal ob-
struction secondary to malignant jejunoileal tu-
mors was 85%6; the findings in this series (82%) arein accord with this incidence. The lack of specific
symptoms and rarity of small-bowel tumors contrib-
ute to advanced stage presentations,7,11,13 stage
presentation is a determinant as a prognostic factor
for adenocarcinoma and sarcoma.2 In our series, 4
patients (2 adenocarcinoma and 2 sarcoma) were
in advanced stages at presentation; all of them sur-
vived from 5 to 37 months. Adenocarcinomas occur
most often in the duodenum, and with diminishing
frequency, in the jejunum and ileum7,11; curiously
all adenocarcinomas in our patients occurred in
the ileum. For GISTs, surgery is the main treat-
ment,9,25,26 however adjuvant therapy with imati-
nib mesylate has a role.4,26 Five of 6 patients with
GISTs had malignant tumors; all of them were com-
pletely resected even with adjacent structures,
and all are still alive with a mean survival time of
27 months (range 14e38 months). We have referred
3 patients for treatment with imatinib mesylate
with good response. Regarding our lymphoma pa-
tients, one presented in Stage 1, two in Stage 2,
and one in Stage 4; none survived more than 2 years
and a few months, they achieved a mean survival
rate of 19 months (range 2e27 months); likely the
cause for this was that the surgical margin was pos-
itive in all 4 patients. Primary and metastatic mel-
anoma, another uncommon malignant GI tumor
found in the jejunum and ileum,27e32 is a rare ma-
lignancy that could lead to intestinal obstruction,29
GI bleeding and chronic anemia.28 We did not find
this tumor in our patients.
In patients with intestinal obstruction, compli-
cations and survival are related to age, associated
morbidity, non-viable strangulation and treatment
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patients with jejunoileal tumors as a cause of their
intestinal obstruction. The reported morbidity rate
for elective patients operated on for small-bowel
tumors was 42%.5 In this series 10 patients (59%)
had postoperative complications, the most com-
mon were surgical site infection and prolonged
postoperative ileus. Two patients developed intes-
tinal fistulas; they were managed conservatively
and closed spontaneously. One patient operated
on for a jejunal lymphoma developed mesenteric
ischemia, intestinal necrosis and sepsis, and died
2 months after the initial surgery. Consequently
our operative mortality rate was 6% comparable
to the 5e32% reported in the literature.5
Most patients with small-bowel malignant tu-
mors have a poor prognosis, however selected
patients undergoing curative resection can achieve
long-term survival.2,5,7,11 The 5-year survival rate
for primary malignant tumors ranges from 5% to
65%, and depends principally on performing a cura-
tive resection at the time of the initial sur-
gery.1,11,12 None of our patients with malignant
tumors survived 5 years. Of them 5 are still alive,
all patients with GISTs, with a survival period rang-
ing from 14 to 38 months. Three patients had
benign tumors (2 leiomyomas and 1 GIST), all are
still alive with a mean survival rate of 72 months
(51e90 months); the reported 5-year survival rate
for benign GISTs ranges from 55% to 58%.12
Conclusions
In this series, jejunoileal tumors presented with
similar frequency in male and female patients,
frequently younger than 49 years of age. Ileal tu-
mors are more likely to develop intestinal obstruc-
tion than jejunal tumors. Emergency surgery for
malignant jejunoileal tumors was associated with
short-term survival, less than 38 months, although
the survival was better for malignant GISTs. How-
ever it should be noted that malignant tumors
like adenocarcinoma, sarcoma and lymphoma pre-
sented more frequently in older patients and GIST
in younger patients. Emergency surgery for these
patients precludes a complete and negative margin
resection (curative resection) and constitutes
a risk factor for residual disease and short-term
survival.
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